Avagenesis Corp. Announces Seven Active Studies With Institutional Review Board (IRB) Approvals

June 6, 2016 - Calgary, Alberta: Avagenesis Corp. (TSXV: VVA) ("Avagenesis" or "Company"), along with co-marketing partner Avapecia Life Sciences Corp. (CSE: VVS), are pleased to announce the arrangement of seven (7) active studies with Institutional Review Board (IRB) approvals for a multitude of indications, to advanced scientific and clinical translational data, using Avagenesis' adipose stem cell isolation platform.

The active studies are being conducted by various distinguished organizations, including the University of British Columbia and Vancouver General Hospital in Canada and Chang Gung Memorial Hospital in Taiwan. In addition, ten (10) new IRB's are in various stages of preparation and approval.

The International Council on Harmonisation (http://www.ich.org) defines an IRB as a committee formally designated to protect the rights, safety and well being of individual participants involved in a clinical trial by reviewing all aspects of the trial before approving its commencement. IRBs are also referred to as Independent Ethics Committees (IEC). The IRB/IEC ensures that clinical trial participants are exposed to minimal risks in relation to any benefits that might result from the research by reviewing the appropriateness of the clinical trial protocol.

"Our teams have worked hard over the last six (6) months to have our cell isolation platform be included in these IRB studies," stated Norman Tsui, CEO of Avagenesis. "The standardization, safety, quick processing time, excellent cell isolation product, automated ease of use and the simple 15 minute user training have all contributed to significant interest from researchers and clinicians alike. Cell therapy can only advance when a cost effective standardized system is available for widespread adoption, supported by a significant base of IRB studies that demonstrate safety and data effectiveness from multi-centre trials."

About Avagenesis Corp.

Avagenesis is a biotechnology company engaged in the commercialization of licensed cell isolation medical technologies for use in regenerative medical aesthetics, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, hepatic disease and kidney disease.

About Avapecia Life Sciences Corp.

Avapecia is a biotechnology company engaged in the research, development and commercialization of regenerative stem cell technologies and therapy solutions for use in urogynaecology, urology, hair loss (prevention, maintenance, and regeneration), gastrointestinal diseases, respiratory medicine, neurodegenerative diseases, ophthalmology, spinal cord injuries and certain autoimmune diseases. Avapecia's bioprocessing platform provides third party validated and standardized isolation of safe, high quality, viable, and potent stem cells from a patient's own fat, or adipose tissue, for use in current and future cell therapy applications.

Neither the TSX Venture Exchange or the Canadian Securities Exchange nor their respective regulation services providers (as that term is defined in their respective policies) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", “likely”, "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that the Company may not successfully transition to a clinical stage company and successfully execute its development and commercialization activities. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company. Readers are cautioned that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Further Information

For further information, please contact:
Avagenesis Corp. or Avapecia Life Sciences Corp.
Alan Tam, CPA, CA
Chief Financial Officer
Telephone: (604) 377-7575